We haven’t had further data doesn’t mean that said further data isn’t being compiled
And it’s only your opinion that there must have been further data to shift its priorities back to BARD1 tests.
BARD1 is further along the pipeline scale because it has been worked on for longer - read much longer.
Progress in most biotechs moves at a snails pace - especially if you are invested in one.
All your posts here range between negative and highly negative so I’ll take them with the grain of salt they deserve
We haven’t had further data doesn’t mean that said further data...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.99M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2115 | 56.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 18000 | 1 |
View Market Depth
| Last trade - 16.12pm 07/06/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |
Day chart unavailable